Wolfe Research analyst Andy Chen initiated coverage of Apellis (APLS) with a Peer Perform rating without a price target The firm says the company’s Syfovre revenue has been “flattish,” with the launch is heading into a “high-scatter” indication where patient-finding may be a challenge. It sees low revenue growth holding back the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $36 from $40 at JPMorgan
- Apellis price target lowered to $19 from $24 at Mizuho
- Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges
- Apellis price target lowered to $45 from $50 at TD Cowen
- Apellis price target raised to $52 from $50 at Baird